Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 741 to 750 of 1090 total matches.
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
as category C (risk cannot be ruled
out) for use during pregnancy.
DRUG INTERACTIONS — Rivaroxaban ...
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement surgery.
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
tandem duplication
(ITD)-positive, newly-diagnosed acute myeloid leukemia
(AML). The drug should ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Botox for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013 (Issue 1414)
) for use during
pregnancy.
DRUG INTERACTIONS — Coadministration of
onabotulinumtoxinA ...
The FDA has recently approved intradetrusor injection
of onabotulinumtoxinA (Botox – Allergan) for treatment
of overactive bladder in patients who cannot tolerate or
have an inadequate response to anticholinergic therapy.
Botox is also approved by the FDA for use in
detrusor overactivity associated with a neurologic condition
such as multiple sclerosis or spinal cord injury,
and for chronic migraine, upper limb spasticity, axillary
hyperhidrosis, cervical dystonia, blepharospasm, strabismus,
and cosmetic reduction of wrinkles.
Sugammadex (Bridion) for Rapid Reversal of Neuromuscular Blockade
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016 (Issue 1502)
observed in exposed rat pups.
DRUG INTERACTIONS — Sugammadex may bind
to progestogens, including ...
The FDA has approved sugammadex (Bridion – Merck),
a selective relaxant binding agent, for reversal of
rocuronium- or vecuronium-induced neuromuscular
blockade in adult surgical patients. It is the first
selective relaxant binding agent to be approved in the
US. Sugammadex has been available in the European
Union, Japan, and elsewhere for several years. Previous
FDA reviews of sugammadex did not result in approval
because of concerns about a risk of anaphylaxis and
other hypersensitivity reactions with its use.
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
who received fosaprepitant and in 2 who
received aprepitant emulsion.3
DRUG INTERACTIONS ...
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1
(NK1) receptor antagonist aprepitant, for prevention
of acute and delayed chemotherapy-induced nausea
and vomiting (CINV) in adults. Aprepitant is also
available in oral capsule and suspension formulations
(Emend, and generics), and fosaprepitant, a prodrug of
aprepitant, is available in an IV formulation (Emend for
injection).
Spinal Decompression Machines
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington ...
Spinal decompression machines offer a motorized form of mechanical traction. These devices, which are widely advertised to the public as a noninvasive alternative to surgery, are claimed to relieve low back pain by decompressing discs, improving the flow of nutrients into the disc and rehydrating dried-out discs. Devices cleared by the FDA based on substantial similarity to previously approved power traction devices include the Accu- Spina System, DRS System, DRX9000, Lordex Traction Unit, Spinal Health Elite, SpineMED Decompression Table, SpineRx-LDM and VAX-D Therapeutic Table.
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
treated with the gene therapy.
DRUG INTERACTIONS — Hydroxyurea, voxelotor,
and crizanlizumab should ...
Two cell-based gene therapies – exagamglogene
autotemcel (Casgevy – Vertex) and lovotibeglogene
autotemcel (Lyfgenia – Bluebird Bio) – have been
approved by the FDA for treatment of sickle cell
disease in patients ≥12 years old with recurrent vaso-occlusive
crises. They are the first gene therapies to
be approved in the US for use in sickle cell disease;
Casgevy is the first treatment to be approved in the
US that uses CRISPR/Cas9 gene-editing technology.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):9-10 doi:10.58347/tml.2024.1694a | Show Introduction Hide Introduction
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
, but they cause
fewer adverse effects than oral antifungals and are
unlikely to interact with other drugs.6 ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Cisapride for Nocturnal Heartburn
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994 (Issue 915)
during pregnancy and lactation.
DRUG INTERACTIONS — Anticholinergic drugs may decrease the effect ...
Cisapride (Propulsid - Janssen), a piperidinyl benzamide prokinetic drug, is now available in the USA for symptomatic relief of nocturnal heartburn due to gastroesophageal reflux disease. In Canada, cisapride is also marketed for treatment of gastroparesis.
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD ...
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.